2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review and share their expert perspectives on key findings in genitourinary malignancies presented at the 2018 ASCO annual meeting.
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS

Genitourinary Cancers

Slidesets KEYNOTE-427 (Cohort A): Phase II Study of Pembrolizumab Monotherapy for First-line Treatment of Patients With Advanced Clear-Cell Renal Cell Carcinoma
Slidesets BLC2001: Phase II Trial of FGFR Inhibitor Erdafitinib in Patients With FGFR-Altered Metastatic or Unresectable Urothelial Carcinoma
Slidesets EV-101: Updated Results From Phase I Study of Enfortumab Vedotin in Patients With Metastatic Urothelial Cancer
Slidesets Phase II ABACUS: Neoadjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (Interim Analysis)
Slidesets Interim Analysis of Phase II PURE-01 Trial: Neoadjuvant Pembrolizumab in Patients With Muscle-Invasive Urothelial Bladder Carcinoma
Slidesets IMmotion151: Patient-Reported Outcomes With First-line Atezolizumab + Bevacizumab vs Sunitinib in Treatment-Naive Metastatic RCC
Slidesets Phase Ib/II Study of Lenvatinib + Pembrolizumab for Patients With Metastatic Renal Cell Carcinoma: Updated Results
Slidesets Phase II Trial: Olaparib + Abiraterone vs Placebo + Abiraterone for Metastatic CRPC Following Chemotherapy
Slidesets KEYNOTE-199: Phase II Study of Pembrolizumab in Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer
Slidesets CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs Sunitinib Alone in Patients With Metastatic Renal Cell Carcinoma

Review the most clinically relevant data on urothelial carcinoma, renal cell carcinoma, and prostate cancer presented at the 2018 ASCO annual meeting in Chicago with this expert analysis and discussion.

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 14, 2018 Expired: No longer available for credit
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo
Contact Info

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue